Phase II study of imatinib in advanced chordoma

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 914-920

  Stacchiotti, Silvia ^a   Longhi, Alessandra ^b   Ferraresi, Virginia ^c   Grignani, Giovanni ^d   Comandone, Alessandro ^e   Stupp, Roger ^h   Bertuzzi, Alexia ^f   Tamborini, Elena ^a   Pilotti, Silvana ^a   Messina, Antonella ^a   Spreafico, Carlo ^a   Gronchi, Alessandro ^a   Amore, Paola ^g   Vinaccia, Vincenza ^g   Casali, Paolo Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e GRADENIGO HOSPITAL   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g Italy   (Italy)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BRIEF PAIN INVENTORY; CHORDOMA; CONTRAST ENHANCEMENT; DRUG TUMOR LEVEL; FATIGUE; FEMALE; FLUID RETENTION; HEMATOLOGIC DISEASE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; TUMOR GROWTH; CLINICAL TRIAL; ENZYME IMMUNOASSAY; IMMUNOPRECIPITATION; ITALY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHORDOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; ITALY; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860610622     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.3656     Document Type: Article

References (49)

1. Newton H: Chordoma, in Raghavan D, Brecher ML, Johnson DH, et al (eds): Textbooks of Uncommon Cancer (ed 3). Chichester, UK, John Wiley & Sons, 2006, pp 614-625
2. Higinbotham NL, Philips RF, Farr HW, et al: Chordoma: Thirty-five-year study at Memorial Hospital. Cancer 20:1841-1850, 1967
3. York JE, Kaczaraj A, Abi-Said D, et al: Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44:74-79, 1999
4. Tzortzidis F, Elahi F, Wright D, et al: Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 59:230-237, 2006
5. Boriani S, Bandiera S, Biagini R, et al: Chordoma of the mobile spine: Fifty years of experience. Spine 31:493-503, 2006 (Pubitemid 43361752)
6. Samii A, Gerganov VM, Herold C, et al: Chordomas of the skull base: Surgical management and outcome. J Neurosurg 107:319-324, 2007 (Pubitemid 47219375)
7. Stacchiotti S, Casali PG, Lo Vullo S, et al: Chordoma of the mobile spine and sacrum: A retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:211-219, 2010
8. Pallini R, Sabatino G, Doglietto F, et al: Clivus metastases: Report of seven patients and literature review. Acta Neurochir 151:291-296, 2009
9. Chambers PW, Schwinn CP: Chordoma: A clinico-pathologic study of metastasis. Am J Clin Path 72:765-776, 1979
10. Bjornsson J, Wold LE, Ebersold MJ, et al: Chordoma of the mobile spine: A clinicopathologic analysis of 40 patients. Cancer 71:735-740, 1993 (Pubitemid 23051375)
11. Bergh P, Kindblom LG, Gunterberg B, et al: Prognostic factors in chordoma of the sacrum and mobile spine: A study of 39 patients. Cancer 88: 2122-2134, 2000 (Pubitemid 30233215)
12. McPherson CM, Suki D, McCutcheon IE, et al: Metastatic disease from spinal chordoma: A 10-year experience. J Neurosurg Spine 5:277-280, 2006 (Pubitemid 47325364)
13. Catton C, O'Sullivan B, Bell R, et al: Chordoma: Long-term follow-up after radical photon irradiation. Radiother Oncol 41:67-72, 1996
14. DeLaney TF, Liebsch NJ, Pedlow FX, et al: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732-739, 2009
15. Ares C, Hug EB, Lomax AJ, et al: Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: First long-term report. Int J Radiat Oncol Biol Phys 75:1111-1118, 2009
16. Crockard HA, Steel T, Plowman N, et al: A multidisciplinary team approach to skull base chordomas. J Neurosurg 95:175-183, 2001 (Pubitemid 32799737)
17. Foweraker KL, Burton KE, Maynard SE, et al: High-dose radiotherapy in the management of chordoma and chondrosarcoma of the skull base and cervical spine: Part 1. Clinical outcomes. Clin Oncol (R Coll Radiol) 19:509-516, 2007
18. Hug EB, Loredo LN, Slater JD, et al: Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 91:432-439, 1999 (Pubitemid 29404435)
19. Noël G, Habrand JL, Mammar H, et al: Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: The Centre de Protontherapie D'Orsay experience. Int J Radiat Oncol Biol Phys 51:392-398, 2001
20. Chugh R, Dunn R, Zalupski MM, et al: Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 23:3597-3604, 2005
21. Scimeca PG, James-Herry AG, Black KS, et al: Chemotherapeutic treatment of malignant chordomas in children. J Pediatr Hematol Oncol 18:237-240, 1996 (Pubitemid 26163488)
22. Razis DV, Tsatsaronis A, Kyriazides I, et al: Chordoma of the cervical spine treated with vincristine sulphate. J Med 5:274-277, 1974
23. McSweeney AJ, Sholl PR: Metastatic chordoma use of mechlorethamine (nitrogen mustard) in chordomas therapy. AMA Arch Surg 79:152-155, 1959
24. Demetri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 9:765-785, 1995
25. Hof H, Welzel T, Debus J: Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 29:572-574, 2006 (Pubitemid 46005781)
26. Singhal N, Kotasek D, Parnis FX: Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 20:953-955, 2009
27. Lindén O, Stenberg L, Kjellén E: Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol 48:158-159, 2009
28. George S, Merriam P, Maki RG, et al: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27:3154-3160, 2009
29. Schönegger K, Gelpi E, Prayer D, et al: Recurrent and metastatic clivus chordoma: Systemic palliative therapy retards disease progression. Anticancer. Drugs 16:1139-1143, 2005 (Pubitemid 41565781)
30. Tamborini E, Miselli F, Negri T, et al: Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA and KIT receptors in chordomas. Clin Cancer Res 12:6920-6928, 2006 (Pubitemid 44974484)
31. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007 (Pubitemid 46797957)
32. Casali PG, Messina A, Stacchiotti S, et al: Imatinib mesylate in chordoma. Cancer 101:2086-2097, 2004 (Pubitemid 39425386)
33. Casali PG, Stacchiotti S, Messina A, et al: Imatinib mesylate in 18 advanced chordoma patients. J Clin Oncol 23:255s, 2005 (suppl; abstr 9012)
34. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
35. Kaplan WE, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
36. Lagonigro MS, Tamborini E, Negri T, et al: PDGFR alpha, PDGFR beta and KIT expression/activation in conventional chondrosarcoma. J Pathol 208:615-623, 2006
37. Tamborini E, Virdis E, Negri T, et al: Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordoma. Neuro Oncol 12:776-789, 2010
38. Stacchiotti S, Tamborini E, Marrari A, et al: Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15:1096-1104, 2009
39. Stacchiotti S, Negri T, Zaffaroni N, et al: Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect. Ann Oncol 22:1682-1690, 2011
40. Tamborini E, Casieri P, Miselli F, et al: Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 212:227-235, 2007 (Pubitemid 46860154)
41. Basciani S, Mariani S, Arizzi M, et al: Expression of platelet-derived growth factor-A (PDGF-A); PDGF-B and PDGF receptor-alpha and -beta during human testicular development and disease. J Clin Endocrinol Metab 87:2310-2319, 2002 (Pubitemid 34521525)
42. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
43. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations - European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782, 1999 (Pubitemid 29512308)
44. Landis JR, Koch JJ: The measurement of observer agreement for categorical data. Biometrics 33:159-174, 1977 (Pubitemid 8054849)
45. Gastrointestinal Stromal Tumor Meta-Analysis Group: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol 28:1247-1253, 2010
46. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008 (Pubitemid 351264358)
47. Shalaby A, Presneau N, Ye H, et al: The role of epidermal growth factor receptor in chordoma pathogenesis: A potential therapeutic target. J Pathol 223:336-346, 2011
48. Han S, Polizzano C, Nielsen GP, et al: Aberrant hyperactivation of Akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 15:1940-1946, 2009
49. Stacchiotti S, Marrari A, Tamborini E, et al: Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 20:1886-1894, 2009